Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in patients ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p 0.0001) - ...

Viridian Therapeutics (VRDN) appears to be ending on a high note in 2024, because it just reported positive results from its phase 3 THRIVE-2 study using its anti-IGF-1R drug veligrotug [VRDN-001] to ...

In the busy pipeline of potential treatments for thyroid eye disease (TED), the novel agent veligrotug showed safety and efficacy in both moderate-to-severe active and chronic TED in the phase 3 ...

H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on VRDN stock, giving a Buy rating today. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily ...

Please provide your email address to receive an email when new articles are posted on . Veligrotug improved proptosis, diplopia and clinical activity score in patients with active or chronic thyroid ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare ...